Safety and efficacy of zetomipzomib in relapsed or insufficiently responding autoimmune hepatitis: Results from the randomized, double-blind, placebo-controlled, phase 2a PORTOLA study and open-label extension. (PubMed, Hepatology) - Sep 23, 2026 - P2 | "Zetomipzomib resulted in numerically higher CR rates than placebo, with evidence of steroid-sparing activity in a difficult-to-treat population, and warrants evaluation in larger randomized studies."
Clinical • Journal • P2a data • Autoimmune Hepatitis • Hepatology • Immunology • Inflammation
|
|
; Aparna Goel; Brian B Tuch; Christopher J Kirk; Craig S Lammert; David Bade; Diana Lam; Eric Lowe; Ethan M Weinberg; Janet L Anderl; Jennifer A Whang; Kathryn Ray; Kiruthi Palaniswamy; Neel K Anand; Rachel Peterson; Robert J Fontana; Seth N Sclair; Shraddha Desai; Tony Muchamuel; Zung To
|